Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-09 |
2024-03 |
-0.69 |
-0.62 |
0.07 |
10.14% |
2024-02-29 |
2023-12 |
-0.76 |
-0.64 |
0.12 |
15.79% |
2023-11-08 |
2023-09 |
-0.75 |
-0.73 |
0.02 |
2.67% |
2023-08-09 |
2023-06 |
-0.69 |
-0.72 |
-0.03 |
-4.35% |
2023-05-09 |
2023-03 |
-0.62 |
-0.63 |
-0.01 |
-1.61% |
2023-03-01 |
2022-12 |
-0.58 |
-0.57 |
0.01 |
1.72% |
Date |
Firm |
Action |
From |
To |
2023-09-21 |
RBC Capital |
Upgrade |
Outperform |
Outperform |
2023-08-21 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2023-08-09 |
Wedbush |
Upgrade |
Outperform |
Outperform |
2023-08-09 |
Needham |
Upgrade |
Buy |
Buy |
2023-07-16 |
RBC Capital |
Upgrade |
Outperform |
Outperform |
2023-06-20 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
Date |
Name |
Relation |
Quantity |
Description |
2022-09-01 |
AULIN SHERRY |
Chief Financial Officer |
0.00 |
Sale |
2023-12-18 |
AZAB MOHAMMAD |
Director |
74.22K |
Conversion of Exercise of derivative security |
2024-03-06 |
GANNON STEVEN |
Director |
2.00K |
Sale |
2024-03-07 |
GAROFALO ELIZABETH A. |
Director |
0.00 |
Sale |
2023-03-23 |
KENNEY CHRISTOPHER JOHN |
Officer |
0.00 |
Sale |
2023-05-23 |
MORTIMER IAN C |
Chief Executive Officer |
45.60K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
FMR, LLC |
5.19M |
199.77M |
8.09% |
2023-06-29 |
Avoro Capital Advisors LLC |
4.90M |
188.65M |
7.64% |
2023-06-29 |
Driehaus Capital Management, LLC |
4.76M |
183.29M |
7.42% |
2023-06-29 |
Polar Capital Holdings Plc |
3.02M |
116.35M |
4.71% |
2023-06-29 |
Capital International Investors |
2.32M |
89.40M |
3.62% |
2023-06-29 |
Marshall Wace LLP |
2.32M |
89.34M |
3.62% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Smallcap World Fund |
4.60M |
176.96M |
7.17% |
2023-08-30 |
Fidelity Select Portfolios - Biotechnology |
961.03K |
37.46M |
1.50% |
2023-07-30 |
Lord Abbett Developing Growth Fund |
912.49K |
33.69M |
1.42% |
2023-07-30 |
Fidelity Advisor Biotechnology Fund |
862.46K |
31.84M |
1.34% |
2023-08-30 |
Fidelity Select Portfolios - Health Care |
800.00K |
31.18M |
1.25% |
2023-07-30 |
Vanguard Specialized-Health Care Fund |
620.63K |
22.91M |
0.97% |